Haleon Pakistan, the consumer healthcare division of the multinational Haleon plc, has announced an investment of $3.58 million to significantly expand the packaging capacity of its popular Panadol Liquid product line.
This capital expenditure is aimed at meeting the growing domestic demand for the pediatric pain and fever relief medication and enhancing the efficiency of the local manufacturing operation.
Investment Details and Strategic Rationale:
- Capacity Enhancement: The investment will fund the installation of new, state-of-the-art automated packaging machinery at Haleon’s manufacturing facility in Pakistan. This will increase production output and streamline the packaging process for Panadol Liquid formats.
- Meeting Market Demand: The expansion is a direct response to consistent growth in consumer demand for trusted, accessible over-the-counter healthcare products within Pakistan.
- Local Manufacturing Commitment: This move reinforces Haleon’s long-term commitment to manufacturing in Pakistan. By investing in local production capabilities, the company aims to ensure a reliable supply of essential products, reduce import dependency, and contribute to the local economy through job preservation and potential creation in technical roles.
A company spokesperson stated, “This investment underscores our confidence in the Pakistani market and our commitment to serving the health needs of Pakistani families. Enhancing our local packaging line allows us to be more agile, efficient, and responsive to the needs of consumers and healthcare professionals across the country.”
The project is expected to be completed within the next fiscal year, after which the increased production capacity will become operational, supporting Haleon’s market leadership in Pakistan’s consumer healthcare sector.
